Inflammatory Bowel Diseases最新文献

{"title":"Erythrocyte Methotrexate-Polyglutamate Concentrations in Pediatric Inflammatory Bowel Disease.","authors":"Eva Vermeer, Eduard A Struys, Marry Lin, Johan E van Limbergen, Nanne K H de Boer, Maja Bulatović-Ćalasan, Tim G J de Meij, Robert de Jonge","doi":"10.1093/ibd/izaf035","DOIUrl":"10.1093/ibd/izaf035","url":null,"abstract":"<p><strong>Background and aims: </strong>Therapeutic drug monitoring (TDM) of methotrexate (MTX) is challenging due to its pharmacokinetics and short plasma half-life. Intracellular MTX-polyglutamates (PG1-5), which accumulate over time, have not been assessed in pediatric inflammatory bowel disease (IBD). This study aimed to evaluate erythrocyte MTX-PG as a potential TDM tool in pediatric IBD.</p><p><strong>Methods: </strong>In this cross-sectional study, MTX-PG concentrations were measured in erythrocytes of children with IBD on stable low-dose MTX for at least 12 weeks using stable-isotope dilution liquid chromatography-tandem mass spectrometry. The influence of administration route, MTX dosage, and anthropometrics on MTX-PG concentrations was examined.</p><p><strong>Results: </strong>Seventy-eight patients were included, showing MTX-PG3 as the predominant subspecies (median 27.0 nmol/L) with a median MTX-PGtotal of 74.8 nmol/L. A higher MTX dose correlated significantly with elevated levels of MTX-PG3, MTX-PG4, MTX-PG5, and MTX-PGtotal (P < .01). Adjusted for body surface area, MTX dose remained significantly associated with higher MTX-PG concentrations (P < .01). However, comparison by administration route was limited due to a few patients on subcutaneous MTX (n = 4).</p><p><strong>Conclusions: </strong>We observed high interindividual variability in the reached erythrocyte MTX-PG concentrations. Body surface adjusted or unadjusted MTX dosage showed a positive linear correlation with erythrocyte MTX-PG concentrations in children with IBD. This is a prerequisite for TDM and provides a strong basis for further research into the relation between TDM of MTX, efficacy, and toxicity.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2503-2510"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12455603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program.","authors":"Gary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, Peter M Irving, Rupa Banerjee, Aline Charabaty, Tanja Kuehbacher, Eustratios Bananis, John C Woolcott, Alexis B Dalam, Krisztina Lazin, Michael Keating, Aoibhinn McDonnell, Silvio Danese","doi":"10.1093/ibd/izae308","DOIUrl":"10.1093/ibd/izae308","url":null,"abstract":"<p><strong>Background: </strong>Patient age can impact the safety and efficacy of ulcerative colitis (UC) treatments. Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. Here, we evaluate the impact of age on etrasimod safety and efficacy in patients with UC in the phase 3 ELEVATE UC clinical program.</p><p><strong>Methods: </strong>Data were pooled from ELEVATE UC 52 and ELEVATE UC 12 in patients receiving etrasimod 2 mg QD or placebo. Proportions and incidence rates (IRs) per 100 patient-years of treatment-emergent adverse events (AEs) were stratified by age (<40, 40-59, and ≥60 years). With the same age stratifications, efficacy was evaluated in patients with baseline Modified Mayo scores of 5-9 and 4-9 for the primary efficacy endpoint (clinical remission) and secondary efficacy endpoints.</p><p><strong>Results: </strong>Overall, 787 patients were enrolled (<40 years, n = 420 [53.4%]; 40-59 years, n = 276 [35.1%]; and ≥60 years, n = 91 [11.6%]). Arthralgia, fatigue, and hypertension IRs were higher in older patients, irrespective of treatment. Serious AEs and AEs leading to treatment discontinuation were low and consistent across age groups. Significantly more patients receiving etrasimod 2 mg QD vs placebo achieved efficacy endpoints, regardless of age.</p><p><strong>Conclusions: </strong>The safety profile of etrasimod 2 mg QD in the ELEVATE UC population was consistent across age groups, with no change in the incidence of AEs. Patients receiving etrasimod vs placebo showed significant clinical benefit, regardless of age.</p><p><strong>Clinicaltrials.gov: </strong>NCT03945188; NCT03996369.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2352-2362"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12455601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Outcomes, Discrimination, and Stigma Among Sexual and Gender Minority People With Inflammatory Bowel Disease.","authors":"Kira L Newman, Patricia A Wren, Millie D Long, Peter D R Higgins","doi":"10.1093/ibd/izaf054","DOIUrl":"10.1093/ibd/izaf054","url":null,"abstract":"<p><strong>Background: </strong>Sexual and gender minority (SGM) individuals often experience more discrimination and worse health than non-SGM people. Less is known about SGM individuals with inflammatory bowel disease (IBD). We studied IBD outcomes, discrimination, illness-related stigma, and SGM status in a cross-sectional survey.</p><p><strong>Methods: </strong>In total, 1586 IBD Partners e-cohort participants self-reported sexual orientation, gender identity, and prior IBD treatment. They completed the Short Crohn's Disease Activity Index or Simple Clinical Colitis Activity Index, the Everyday Discrimination Scale, and the Paradox of Self Stigma (PASS-24) scale. We performed regression analyses controlling for age, race, disease duration, and IBD type.</p><p><strong>Results: </strong>SGM people were 7.8% (n = 124) of the cohort. SGM participants were younger than non-SGM participants (median age 40 vs. 54 years, P < .001). Among SGM individuals, 67% (n = 74) were in remission based on disease activity scores. Among non-SGM individuals, 74% (n = 936) were in remission (P = .097). Similar proportions of SGM and non-SGM persons reported prior IBD-related hospitalization (40% vs. 37%, P = .426; adjusted odds ratio [aOR] 0.95, 95% confidence interval [CI], 0.62-1.45) and IBD-related surgery (52% vs. 54%, P = .707, aOR 1.25, 95% CI, 0.81-1.94). SGM respondents reported more discrimination (71% vs. 47%, P < .001), and 43% of SGM individuals reported healthcare-related discrimination versus 21% of non-SGM individuals (P < .001). SGM persons also endorsed more internalized stigma (median PASS-24 scores 53 vs. 47, P = .026).</p><p><strong>Conclusions: </strong>SGM individuals with IBD are more likely to experience discrimination, including in healthcare, and illness-related stigma. These may significantly impact the quality of life and should be considered in the care of SGM people with IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2429-2437"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12455600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission.","authors":"Katie A Dunleavy, Chad R Rypstra, Irene Busciglio, Deborah Eckert, Michael Ryks, Ellie Omerdic, Victor G Chedid, Laura E Raffals, Michael Camilleri","doi":"10.1093/ibd/izaf043","DOIUrl":"10.1093/ibd/izaf043","url":null,"abstract":"<p><strong>Background and aims: </strong>Inflammatory bowel disease (IBD) is associated with altered mucus and increased intestinal permeability (IP). Prior reports on permeability in IBD typically used lactulose-to-mannitol ratio (LMR). Food contamination with 12C-mannitol is a significant potential confounder in IP assessment. We aimed to compare small intestinal (SI) and colonic (COL) permeability in IBD, both active (ACT) and in remission (REM), to normal healthy volunteers (NHV).</p><p><strong>Methods: </strong>Inflammatory bowel disease activity was based on Simple Endoscopic Score for Crohn's Disease (SES-CD) and Mayo endoscopy score for ulcerative colitis (UC). We performed 24-hour IP test using 100 mg 13C-mannitol and 1000 mg lactulose with urine collected during 0-2, 2-8, and 8-24 hours. The primary endpoint was mg excretion of 13C-mannitol and lactulose during 2-24 hours reflecting SI and COL permeability.</p><p><strong>Results: </strong>Among 17 CD patients, 7 were ACT (SES-CD >6), and 10 REM (SES-CD 0-2). Among 20 UC patients, 10 had ACT (Mayo score 2-3), and 10 REM (Mayo score 0-1). Urinary excretions over 2-24 hours were higher for IBD than NHV: 13C-mannitol (13.8 [IQR 8.8, 18.7] NHV; 18.4 [15.6, 29.9] REM; 19.7 [13.8, 23.6] ACT, P = .003) and lactulose (1.8 [1.3, 3.1] NHV; 3.6 [2.0, 5.0] REM; 3.5 [2.0, 6.6] ACT, P = .006). There was no difference between ACT and REM for any timed urine collection. LMR at 2-24 hours (or 2-8 and 8-24 hours) were not statistically significant between the 3 groups (0.014 [0.010, 0.021] NHV; 0.016 [0.010, 0.023] REM; 0.016 [0.012, 0.038] ACT, P = .237).</p><p><strong>Conclusions: </strong>Intestinal permeability is increased in IBD using validated in vivo assay relative to NHV; increased IP in IBD persists during remission.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2511-2520"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12455586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal Microbial Community Profiling Allows Discrimination of Phenotype and Treatment Response in Pediatric Crohn's Disease and Ulcerative Colitis-An International Meta-Analysis.","authors":"Denise Aldrian, Adam Pollio, Christoph Mayerhofer, Kay Diederen, Jonathan P Jacobs, Nikhil Pai, Jake C Szamosi, Lara Hart, Dan Turner, Federica Del Chierico, Sabrina Cardile, Zoya Grigoryan, Lea Ann Chen, Jakub Hurych, Ondrej Cinek, Carla R Taddei, Tobias Schwerd, Eytan Wine, Anne M Griffiths, Thomas Müller, Georg F Vogel","doi":"10.1093/ibd/izaf135","DOIUrl":"10.1093/ibd/izaf135","url":null,"abstract":"<p><strong>Background and aims: </strong>The pathophysiology of pediatric inflammatory bowel disease (PIBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is not entirely understood. Dysregulation of the intestinal microbiome is recognized as both a disease-driving and a potential therapeutic target. This study aimed to systematically analyze gut microbiome compositions and its applicability as a biomarker for disease progress and treatment response.</p><p><strong>Methods: </strong>Bibliographic and nucleotide databases were searched. Raw 16S-rRNA sequencing reads were subjected to a uniform downstream dada2/phyloseq pipeline to extract taxonomy, community structure, and abundance information. Patient metadata were extracted from publications, and study authors were contacted for further details if required.</p><p><strong>Results: </strong>Twenty-six studies comprising 3956 stool samples (CD 41%, UC 36%, 23% healthy) were included in the analyses. Median age of individuals was 12 (interquartile range 4). Sex distribution was comparable. Alpha diversity was reduced between the healthy and both UC and CD treatment-naïve groups (P < .001) and further reduced with increasing clinical disease activity. Beta diversity revealed altered community structure in treatment-naïve children with PIBD (P < .001). This alteration remained in patients in clinical remission (P < .001). Machine learning models discriminated between treatment-naïve patients with CD or UC with an area under the receiver operating characteristics curve (AUROC) of 98%. Microbial communities differed between patient responders versus nonresponders to treatment (P < .001). Further, microbial community profiling distinguished treatment response (eg, steroid, nutrition, or TNFα) with AUROCs of 82%-90%.</p><p><strong>Conclusions: </strong>Gut microbial community structure is substantially altered in active and inactive PIBD and may be utilized as a biomarker for differentiating PIBD subtype and predicting treatment response.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2338-2351"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12455605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn's Disease Activity: A Prospective Cross-Sectional Study.","authors":"Natsuki Ishida, Satoshi Tamura, Tomohiro Takebe, Kenichi Takahashi, Yusuke Asai, Tomoharu Matsuura, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Takanori Yamada, Satoshi Osawa, Ken Sugimoto","doi":"10.1093/ibd/izaf025","DOIUrl":"10.1093/ibd/izaf025","url":null,"abstract":"<p><strong>Background: </strong>The goal of treatment for Crohn's disease (CD) is to achieve mucosal or transmural healing, and biomarker measurements are useful in monitoring disease activity and guiding treatment. This study aimed to investigate the utility of a new urinary biomarker, prostaglandin E-major urinary metabolite (PGE-MUM), in assessing CD activity.</p><p><strong>Methods: </strong>The study involved 87 patients with CD who underwent endoscopic examination and measurements of 4 biomarkers: Prostaglandin E-major urinary metabolite, fecal calprotectin (FC), leucine-rich α2 glycoprotein (LRG), and C-reactive protein (CRP). Endoscopic activity was assessed by the Simple Endoscopic Score for Crohn's Disease (SES-CD). Correlations between the CD activity index (CDAI) and SES-CD with the 4 biomarkers were analyzed, and receiver-operating characteristic (ROC) analyses were performed to predict SES-CD ≧ 3.</p><p><strong>Results: </strong>All 4 biomarkers showed significant correlations with both CDAI and SES-CD. The cutoff (area under the curve [AUC]) values for predicting SES-CD ≥ 3 were as follows: PGE-MUM, 25.2 µg/g Cr (0.800); FC, 257 mg/kg (0.816); LRG, 11.8 µg/mL (0.748); and CRP, 0.22 mg/dL (0.656). Subgroup analysis revealed significant correlations between PGE-MUM and SES-CD in both the L1 (small intestine only) and L2 + L3 (including large intestine) groups, with correlation coefficients of 0.654 and 0.586, respectively. In the L1 group, ROC analysis revealed that, among the 4 biomarkers, PGE-MUM had the highest AUC for predicting SES-CD ≥ 3, with a cutoff (AUC) of 33.1 µg/g Cr (0.861).</p><p><strong>Conclusions: </strong>PGE-MUM is a biomarker that can reflect endoscopic activity in patients with CD and may be particularly useful in small intestinal lesions.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2420-2428"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Vancomycin as an Emerging Therapy for Inflammatory Pouch Conditions Associated With Primary Sclerosing Cholangitis.","authors":"Katie Dunleavy, Abigail Meyers, Tommaso Violante, Blake Kassmeyer, Siri A Urquhart, Nayantara Coelho-Prabhu, Laura Raffals, David Larson","doi":"10.1093/ibd/izaf117","DOIUrl":"10.1093/ibd/izaf117","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2597-2601"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Human Leukocyte Antigen Alleles and Maternal Microchimerism in Very-Early-Onset Ulcerative Colitis in Japanese Children.","authors":"Masanori Toda, Keisuke Jimbo, Mitsuyoshi Suzuki, Masumi Nagata, Nobuyasu Arai, Kaori Tokushima, Eri Miyata, Yuka Nagano, Yuki Koike, Keiichi Uchida, Takahiro Kudo, Yuji Toiyama, Toshiaki Shimizu","doi":"10.1093/ibd/izaf048","DOIUrl":"10.1093/ibd/izaf048","url":null,"abstract":"<p><strong>Background: </strong>Very-early-onset ulcerative colitis (VEO-UC) is a severe form of inflammatory bowel disease that manifests before the age of 6 years. Compared to typical pediatric UC, it is characterized by distinct genetic and immunological factors. This study aimed to investigate the roles of specific human leukocyte antigen (HLA) alleles and maternal microchimerism (MMc) in the pathogenesis of VEO-UC in a Japanese population.</p><p><strong>Methods: </strong>This study included 27 VEO-UC patients, including 4 patients treated with colorectal resection. HLA typing was performed by polymerase chain reaction-sequence-specific oligonucleotide probing (PCR-SSOP) and compared with the Japanese general population. Immunohistochemistry and fluorescence in situ hybridization were used to evaluate MMc in intestinal tissues. Statistical comparisons of HLA were performed against data from the general Japanese population, with Bonferroni corrections applied to handle multiple comparisons.</p><p><strong>Results: </strong>HLA-B52 and HLA-DR15 were more prevalent in cases of VEO-UC than in the general Japanese population, although the statistical significance decreased after the Bonferroni correction. MMc was found in the intestinal tissues of three VEO-UC cases, whereas it was absent in the control UC cases. Maternal HLA concordance with specific alleles associated with VEO-UC was noted in several cases, suggesting maternal immune involvement in the pathogenesis of the disease.</p><p><strong>Conclusions: </strong>VEO-UC seems to share genetic traits with adult UC, such as an association with HLA-B52 and HLA-DR15, and is also affected by maternal immune contributions, as shown by the presence of MMc in the affected tissues. These findings highlight the complex interaction between genetic and immunological factors in the pathogenesis of VEO-UC and underscore the need for further research to develop targeted therapeutic strategies that address these mechanisms.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2451-2457"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of Extraintestinal Manifestations in Patients With Ulcerative Colitis Post-Restorative Proctocolectomy and Ileal Pouch-Anal Anastomosis: A Single-Center Retrospective Study.","authors":"Alex Barenboim, Tali Epstein Weiss, Orestis Argyriou, Nathaniel Aviv Cohen, Yehuda Kariv, Meir Zemel, Eran Itzkowitz, Ron Greenberg, Noam Goder, Sara Borok, Kapil Sahnan, Hagit Tulchinsky, Nitsan Maharshak","doi":"10.1093/ibd/izaf037","DOIUrl":"10.1093/ibd/izaf037","url":null,"abstract":"<p><strong>Background and aims: </strong>Extraintestinal manifestations (EIMs) are common in patients with ulcerative colitis (UC). However, the prevalence and associated factors of EIMs in UC patients post-restorative proctocolectomy with ileal pouch-anal anastomosis (RPC + IPAA) are not well established.</p><p><strong>Methods: </strong>We extracted clinical, demographic, and laboratory data of all UC patients who underwent IPAA surgery and followed up in our comprehensive pouch clinic between 2003 and 2021. EIMs were classified as musculoskeletal, mucocutaneous, ophthalmologic, and hepatic, and their frequency before and after the IPAA surgery was assessed. Univariate and multivariate analyses were performed to detect factors associated with EIMs.</p><p><strong>Results: </strong>Included were 310 post-IPAA patients with a follow-up of 103.5 (1-250) months. EIMs were documented in 145/310 (46.78%) patients. Of them, 97 (66.9%) had musculoskeletal, 11 (7.59%) had mucocutaneous, 15 (10.34%) had hepatic, and 22 (15.17%) had a combination of 2 EIMs (including 3 ophthalmic cases). Preoperative EIMs were documented in 87/310 (28.1%) patients, and they persisted after the IPAA surgery in 72/87 (82.75%). The preoperative presence of musculoskeletal EIMs (odds ratio [OR]: 8.2, 95% confidence interval [CI]: 4.1-16.7, P = .0001), postoperative chronic pouchitis, and/or Crohn's-like disease of the pouch (OR: 2.2, 95% CI: 1.2-4.1, P = .01), as well as non-Ashkenazi origin (OR: 2.1, 95% CI: 1.1-3.9, P = .01) were associated with the prevalence of postoperative EIMs on a multivariate analysis.</p><p><strong>Conclusions: </strong>The EIM rate increases post-IPAA surgery in UC patients, and most preoperative EIMs do not resolve. Awareness of the factors associated with EIMs will enable earlier detection and management for improving patient well-being and quality of life.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2467-2476"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multifaceted Endoscopic Approach (Stricturotomy, Balloon Dilation, Fistulotomy, and Seton Placement) Guided by Intestinal Ultrasound to Avert Surgery in Complicated Crohn's Disease During Lactation.","authors":"Partha Pal, Mohammad Abdul Mateen, Rajesh Gupta, Manu Tandan, D Nageshwar Reddy","doi":"10.1093/ibd/izaf076","DOIUrl":"10.1093/ibd/izaf076","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2602-2603"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}